Desmopressin EP Impurity A is a reference impurity standard reflecting a closely related structural variant of desmopressin. Changes in residue connectivity or oxidation state alter chromatographic and spectrometric signatures. Researchers use it to verify analytical selectivity and quantify trace levels in formulations. Applications include impurity profiling, stability-indicating method development, and peptide-process optimization.
CAT No: R2743
Synonyms/Alias:[5-L-aspartic acid]desmopressin;2-((4R,7S,10S,13S,16S)-4-((S)-2-(((R)-1-((2-amino-2-oxoethyl)amino)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidine-1-carbonyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-7-yl)acetic acid
Desmopressin EP Impurity A is a structurally defined peptide impurity associated with the synthesis and characterization of desmopressin, a synthetic analog of vasopressin. As a well-characterized peptide standard, it plays a critical role in the quality assessment and regulatory compliance of pharmaceutical preparations containing desmopressin. Its unique sequence and physicochemical properties make it an essential tool for researchers and analytical chemists involved in peptide drug development, impurity profiling, and method validation. The availability of this impurity in pure, isolated form supports rigorous scientific investigation into the identity, behavior, and impact of minor peptide components within complex formulations.
Analytical Method Development: Desmopressin EP Impurity A serves as a vital reference material in the development and optimization of chromatographic and mass spectrometric methods for impurity detection and quantification. By providing a known standard, it enables analysts to establish retention times, fragmentation patterns, and calibration curves, thereby ensuring high specificity and sensitivity in impurity profiling. This is especially important for laboratories developing robust HPLC, UPLC, or LC-MS methods for regulatory submissions or routine quality control.
Quality Control and Batch Release: In pharmaceutical manufacturing, accurate identification and quantification of process-related impurities are critical for batch release and product safety. The use of Desmopressin EP Impurity A allows quality control laboratories to verify the presence and concentration of this specific impurity in desmopressin active pharmaceutical ingredients (APIs) and finished products. Its inclusion in analytical protocols helps ensure that impurity levels remain within acceptable limits, supporting compliance with pharmacopeial requirements and minimizing the risk of product recalls due to impurity-related issues.
Peptide Synthesis Process Optimization: During the solid-phase or solution-phase synthesis of desmopressin, minor by-products such as EP Impurity A can arise due to incomplete reactions, side-chain modifications, or sequence deletions. Monitoring the formation of this impurity provides valuable feedback on the efficiency and selectivity of peptide coupling steps. Researchers can use this information to refine synthetic protocols, adjust reagent concentrations, or modify purification strategies, ultimately enhancing the overall yield and purity of the target peptide.
Stability Studies: The presence and behavior of Desmopressin EP Impurity A under various storage and stress conditions offer insights into the degradation pathways of peptide formulations. By incorporating this impurity into forced degradation and long-term stability studies, scientists can better understand the chemical and physical factors that influence peptide stability. These findings inform the development of improved formulation strategies, packaging solutions, and storage recommendations for desmopressin-containing products.
Pharmacopoeial Compliance and Reference Standardization: For laboratories tasked with meeting European Pharmacopoeia (EP) monograph requirements, the availability of Desmopressin EP Impurity A as a well-defined reference standard is indispensable. It enables precise alignment with compendial test methods, facilitates inter-laboratory comparisons, and supports the accurate assignment of impurity thresholds. By serving as a benchmark for both internal and external quality assessments, this impurity standard underpins the integrity and reproducibility of analytical data across the pharmaceutical industry.
1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
2. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
3. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More